Q-omics provides the consensus-scored LRRC10B profile across patient tissues and cancer cell-line models. LRRC10B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LRRC10B is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, LRRC10B RNA expression shows 14,830 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where LRRC10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC10B survival associations across molecular data types. LRRC10B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC10B RNA expression–survival associations across cancer types. High LRRC10B expression shows unfavorable associations in KIRP, UVM, ACC and BLCA, but favorable associations in LUAD and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LRRC10B RNA expression.
This table summarizes LRRC10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC10B shows lower tumor expression in KICH, KIRP, LUSC and LUAD and higher tumor expression in LIHC and COAD. The KICH box plot shows higher LRRC10B RNA expression in normal versus tumor tissue (log2 FC = −1.788, t-test p < 0.001).
This table shows molecular features associated with LRRC10B in patient tissues and cancer cell lines. In patient samples, LRRC10B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
